Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology
Radek Pudil(Charles University), Alexander R Lyon(Royal Brompton Hospital), Teresa López‐Fernández(Hospital Universitario La Paz), Peter Henriksen, Thomas Suter, Frank Ruschitzka(University Hospital of Zurich), Zaza Iakobishvili(Tel Aviv University), Javid J. Moslehi(University of California, San Francisco), Daniela Cardinale, Dan Lenihan(Washington University in St. Louis), Ana Barac(National Institute of Dental and Craniofacial Research), Rudolf A. de Boer(University Medical Center Groningen), Stephan von Haehling(University of Göttingen), Jelena Čelutkienė, Susan Dent(Government of the United States of America), Christoph Maack(Comprehensive Cancer Center Mainfranken), Andrew J.S. Coats(IRCCS Ospedale San Raffaele), Susanna Stanway(Royal Marsden NHS Foundation Trust), Fortunato Ciardiello(University of Naples Federico II), Martin Štěrba(Charles University), Mitja Lainščak, Carlo G. Tocchetti(Federico II University Hospital), Dimitrios Farmakis, Ovidiu Chioncel, Eva Haegler‐Laube(University of Bern), Riccardo Asteggiano, Jutta Bergler‐Klein, Petar Seferović, Jean‐Sébastien Hulot(Inserm), Alain Cohen‐Solal(Hôpital Lariboisière), Bonnie Ky(Washington Hospital), Hadi Skouri(American University of Beirut Medical Center), Massimo Piepoli, Christian Mueller(University of Basel), Markus S. Anker(Berlin-Brandenburger Centrum für Regenerative Therapien), Jereon Bax(Leiden University), Yu. N. Belenkov
Cited by 344
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k